Physician profile
Michael A Mcmann
NPI 1215941190
$4,331.79
in general payments reported to CMS, 2019-2025
19 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,984 · 2020: $156 · 2021: $309 · 2022: $872 · 2023: $349 · 2024: $253 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,676.17 | 2019-2022 | |
| Alcon Vision LLC | $663.25 | 2021-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Aerie Pharmaceuticals, INC. | $271.58 | 2019-2021 | |
| Dompe US, INC. | $243.33 | 2022 | |
| Sun Pharmaceutical Industries INC. | $234.81 | 2019-2022 | |
| Horizon Therapeutics Plc | $194.03 | 2022-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $181.47 | 2022-2024 | Miebo |
| Amgen INC. | $169.79 | 2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $154.95 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $138.13 | 2021 | |
| Abbvie INC. | $123.06 | 2022-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $117.29 | 2019-2021 | |
| Sight Sciences, INC. | $41.38 | 2021-2025 | Sion Surgical Instrument, Omni Surgical System |
| Kala Pharmaceuticals, INC. | $36.78 | 2021-2022 | |
| Harrow Eye, LLC | $24.94 | 2025 | Verkazia, Natacyn, Flarex |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $23.28 | 2024 | Xdemvy |
| Allergan, INC. | $18.56 | 2020 | |
| Beaver-Visitec International, INC. | $18.16 | 2025 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.